Stem Cell Clinic

World-Renowned Stem Cell Transplantation Expert joins Cellect’s Advisory Board – P&T Community

By Stem Cell Medicine
World-Renowned Stem Cell Transplantation Expert joins Cellect's Advisory Board
P&T Community
"Dr. Cutler is world renowned for his contributions to innovations within the stem cell transplantation industry to drive potential treatments in cancer and many other medical conditions, said Dr. Shai Yarkoni, Cellect's CEO. We look forward to ...

and more »

Here is the original post:
World-Renowned Stem Cell Transplantation Expert joins Cellect's Advisory Board - P&T Community

SA-Based INCELL’s Innovation to Fuel Biomanufacturing Market – Rivard Report

By Uncategorized

Business & Tech By Iris Gonzalez | 6 hours ago

Scott Ball / Rivard Report

Scientists work in the product formulation room which is part of the biomanufacturing suite at INCELL.

The United States is a leader in engineering biology research and supporting science and technology fields. However, both local and national markets need further investment to translate the development of these new tools into robust technologies that will support reproducible biomanufacturing.

With its unique business model and advanced research and technologies, San Antonio-basedbiomedical products manufacturer INCELL is on a mission to propel biomanufacturing in regenerative medicineforward.

Research in regenerative medicine requires specialized expertise, facilities, and sizable amounts of capital. Work on regenerative tissue engineering using molecular biology as the foundation for replacing, engineering, or regenerating human cells, tissues, or organs to restore or establish normal function also requires biotechnology manufacturing, a vital part of growing the biotech ecosystem that isnt discussed as much.

With attention focused on how advanced manufacturing is growing across industry sectors, the Rivard Report visitedINCELLs headquartersoff I-10 and DeZavalato learn more about the state of the biomanufacturing industry.

INCELL is a biomedicine products manufacturer and contract services provider, which manufactures and develops effective treatments for unmet medical needs conditions for which there exists no satisfactory method of diagnosis, prevention, or treatment.

Were at the precipice of total kick ass cell biotechnology, INCELL founder, Chief Science Officer, and CEO Dr. Mary Pat Moyer said.

Scott Ball / Rivard Report

Dr. Mary Pat Moyer is founder and chief science officer at INCELL.

A biomedical scientist, entrepreneur, and technology business leader with more than four decades of experience in business and science, Moyer was a professor of surgery but is not a surgeon. In 1981 she became the first female faculty member in the UT Health San Antonio Long School of Medicines department of surgery and their first Ph.D. (rather than an M.D.) professor.

Moyers path has been a nontraditional one, and it has served her well in the fields of regenerative medicine and infectious diseases. INCELLs main business units are in cell and tissue therapies as well as vaccines and infectious diseases.

Things have changed so much, as in the tools and the science, especially the cell biology and genetics, Moyer said. I started out as a basic scientist, trained in microbiology and molecular virology. A virologist has to know cells well because viruses are intracellular parasites.

Moyer brought that cellular knowledge to the medical schools surgery department, where she was hired to create research in the department. Moyer developed her knowledge base in what is now known as regenerative medicine cell, tissue, and gene technologies, tools, and therapies.

Since Moyer founded INCELL in 1993, the company has developed unique formulas of manufactured sterile media and cell culture products which have been shipped worldwide over the past 10-12 years. This includes two unique INCELL human colon cell lines licensed for research use in cancer, nutrition, environmental, and cell biology studies. INCELL also does contract services for the development, manufacturing, research, and testing of cells, tissues, vaccines, and solutions, thus helping many biotech companies globally.

The media solutions and reagents are part of human tissue bioprocessing used either as direct products or grown as replicating cell cultures which INCELL cryostores in suspended amination. Scientists and doctors use these stored tissues, stem cells, and functional cells to help patients suffering from arthritis, cancer, neural degeneration, cardiovascular diseases, and damaged tissues needing renewal and repair, to name a few applications.

The pathway from concept to patient use requires biomanufacuturing, which INCELL specializes in.

Moyer sees a gap in scientists and the publics knowledge when it comes to commercializing a medical product. It takes more than a good idea and money; an educated workforce, sustained funding streams, quality product manufacturing, and an understanding of the market are also essential.

When people talk about [taking an idea from] bench to bedside, theres typically no mention of manufacturing, Moyer explained. People may think manufacturing is blue collar, but its critical in order to get anything to the clinic when the patient can use the product.

INCELL, Moyer stressed, is a small biotech business, rather than a venture capital fueled company. It is difficult and takes longer to go this route, but Moyer has focused on building a strong foundation in a company with well-trained staff, quality contract services, and innovative biotech products for the clinical market.

You have to work out your basic manufacturing, product release, and safety protocols scientists typically dont have training [in]this aspect of commercialization, Moyer added. As a business owner I have to invest huge amounts of time and resources to train staff. Young people out of school and university labs may have a good knowledge of conceptual science and general procedures; however, they are inadequately prepared to work in their scientific discipline in industry.

INCELL wasbuilt as a collaborative industry-research-government-education biotech company business model with capital from product sales, competitive contracts, and government small business grants. It adopted a different business model for personalized stem cell medicines with collection and manufacturing kits for specific medical needs. INCELLson-site cryostorage facility uses itsworld-class solutions to store human cells and tissues intended for clinical use.

We cryostore tumor cells and blood cells from patients at our facility, Moyer said. We can grow those cells, and then work as part of a clinical discovery team with medical professionals, scientists, other labs, and patients to help determine if there are personalized therapies such as targeted drugs or vaccines for cancer or immunotherapies that could be developed to treat a specific patients disease.

However, Moyer decided a new collaborative team approach with multiple companies would lend itself bestto supporting the research, development, and commercialization of so many new and different therapies.

In 2016, Moyer set up the Foundation for Cell, Gene and Tissue Innovations (CGTI) as a nonprofit that participates in tissue or cell collections and accepts charitable donations for research, product development, and pre-clinical and clinical testing of manufactured products. Moyer also formed4RMED to oversee clinical trials and regulatory needs for CGTI, INCELL, and their clients. 4RMED oversees the human subjects research protocols, manages Investigational New Drug Applications (INDs) for drugs and biological products, and prepares documents in support of medical devices and combination products applications.

Our vision for personalized medicine is that we will have components ready to go on site at INCELL or on location with qualified hospital or clinical partners, Moyer explained. For a patient presenting with a targeted disease, INCELL or its collaborating clinical sites, could offer off-the-shelf processes, products, or participation in ongoing clinical studies for a faster response time.

With projects and products in the queue that address unmet medical needs and many targeted diseases, the cell therapy products will be commercialized by new spin-off companies funded through private and public investors and supported through INCELLs affiliated incubator company TEKSA Innovations Corp.

In June 2016, INCELL announced its new partnership with a Belgian investor group formed by Wisetree Invest and 4 for Cells, expected to fuel 50 new jobs at INCELLs headquarters in San Antonio over the short term. The resulting joint venture companyBioturnkeywill have a U.S. location in San Antonio and a site in Belgium.

Moyer opted for a collaborative partnership with INCELL and Bioturnkey working in both the U.S. and Europe. The parallel development of biotech products with coordinated manufacturing and commercialization in both markets would reduce delays, costs, and complications for new products entering the clinical markets in both places. By working in tandem, the partners can ensure products meet regulatory requirements so products are ready in about the same time frame in both markets.

The Bioturnkey businessplan is to accelerate developing personalized medicine and cell therapy products by linking INCELLs quality manufacturing technologies with closed bio-isolators and ready-to-go systems in Europe and the U.S. Moyer described this collaborative approach as a startup accelerator because the newly created companies can take advantage of manufacturing expertise and techniques already in place at INCELL and, therefore, get products to market faster.

According to Moyer, its an exciting time to be working at the forefront of regenerative medicine. It is my passion and my lifes work to see these products get to the clinic, shestressed.

The leveraged, collaborative support via CGTI, INCELL manufacturing and testing, 4RMED clinical trials, TEKSA incubation of new companies, and collaborative business initiatives with Bioturnkey and other entities in the U.S. and globally, should help catapult San Antonios growing regenerative medicine industry forward.

Iris Gonzalez is a contributing writer covering technology, life science, and veteran affairs for the Rivard Report. A first generation Cuban American, she is also a strategic planning consultant for nonprofit and government sectors and a docent at the San Antonio Museum of Art.

Go here to read the rest:
SA-Based INCELL's Innovation to Fuel Biomanufacturing Market - Rivard Report

‘Small Town Throwdown’ for Zach Standen on March 11 – The Redding Pilot

By Uncategorized

Bobby Paultauf and his band will play the throwdown.

Those in the Redding, Easton area are probably aware of what happened to Joel Barlow High School student Zach Standen in the summer of 2016. Zach was in a devastating auto accident that left him partially paralyzed.

He needs hope and support from as many people as possible. He needs countless medical procedures in order to gain movement to his legs again through stem cell treatment due to a tragic car accident that made him paralyzed.

To help support Standens recovery, local musicians Bobby Paltauf, of the Bobby Paltauf Band, and Grayson Hugh, of Grayson Hugh & the Moon Hawks, will play a benefit show on Saturday, March 11 at the Fairfield Theater Company.

The family has started a GoFundMe account where people are able to donate to this expensive treatment. Lets all get together and help him walk again, Paultaufs mother, Tiffany, wrote in a press release.

Bobby Paltauf is a senior at Joel Barlow High School, where Standen goes.

Lets all get together and support local live music, especially where it benefits the hope of Zach being able to walk again, his mother wrote.

For the concert benefitting Standen, more information can be found on The Bobby Paltauf Band page on Facebook, and tickets are available at http://www.fairfieldtheatre.org.

Zach Standen coached soccer Oct. 8 at Seaside Park in Bridgeport with, back row, left to right, Mark Roman, Alastair Bruce and Peter Syku.

Standen may be helped by stem cell medical treatments that can be administered in Panama.

The Standen family is in discussions and communication with the Cell Medicine Institute in that country and are pursuing this line of treatment for the young man, who is paralyzed.

We have done much research into stem cell therapy for spinal cord injuries here in the U.S. and Canada, and there just are no clinical trials or clinics that have the experience and track record like this one, the family said in a recent letter. Cell Medicine has been doing this specific treatment since 2006 and has a 60% to 70% success rate of some kind of improvements in most patients within a year.

Each procedure costs $37,200, which includes all medical procedures and ancillary needs. This is not covered by medical insurance.

The family is hoping everyone reading this could go to his GoFundMe page and donate $25, to help Zachs recovery.

To donate, visit: https://www.gofundme.com/stem-cell-therapy-for-zach-standen.

Continue reading here:
'Small Town Throwdown' for Zach Standen on March 11 - The Redding Pilot

Generous Teessiders fund mum’s 15000 trip to China for stem cell treatment – Gazette Live

By Stem Cell Treatment

A MUM has China in her sights thanks to the kindness of Tessiders.

The Gazette told last October how Teesville mum Jodie Hardwick, 29, was diagnosed with a muscle-wasting condition when she was 11 and has coped with life in a wheelchair - and deteriorating sight - ever since.

Her failing eyesight means she can only see children Rhys and Sian in silhouette - but pioneering stem cell surgery in China could change all that.

And thanks to the generosity of family, friends and many people she doesnt even know, shell be heading to the Far East in May.

With more than 12,000 of her 15,000 target raised, it means Jodie, mum Michelle and her aunty Julie Allport will be jetting out to Hong Kong at the end of May before travelling to the Shixin Hospital in Dongguan, on the Chinese mainland.

Its hoped the treatment she receives there, while not offering a cure for her Friedrichs Ataxia, could slow its progress and even bring back some of Jodies sight, hearing and muscle function.

Treatment on people with similar conditions has seen some improvement with their sight, speech and muscle control.

Its been a whirlwind few months of fundraising for the family - and theyre eager to say thanks to everyone who has helped.

Larger donations have included 2,500 from a fundraising night at the Dormans club in Middlesbrough, 1,000 from Blueline and Marton Taxis and 1,430 from two bucket collections at the Waterloo Road mosque in Middlesbrough.

The Club Bongo International, the Red Lion in Linthorpe and family and friends have also helped hugely with fundraising.

Mum Michelle said: Weve got most of the money in now - we just need that final push to reach the 15,000.

People have donated through the GoFundMe page but its mainly been through direct donations.

Its been unbelievable really, were so grateful. Jodies quiet astonished and excited - she didnt think it was going to happen.

Were flabbergasted at how generous people have been.

Visit http://www.gofundme.com/2tkcv4s.

Visit link:
Generous Teessiders fund mum's 15000 trip to China for stem cell treatment - Gazette Live

Steenblock Research Institute Announces New Method of Obtaining … – PRUnderground (press release)

By Stem Cell Clinic

The treatment of chronic diseases and medical conditions using a patients own stem cells is an exciting, dynamic area of medicine that is enjoying unprecedented success thanks to a combination of new discoveries and impressive patient responses. Here in the US, over 600 private clinics are doing stem cell therapies, most using stem cells taken from a patients own bone marrow or fat tissue.

Unfortunately, many ailing people are reluctant or unable to undergo the harvesting of bone marrow or fat tissue. With this in mind, physician David Steenblock, president of the nonprofit Steenblock Research Institute (SRI), asked the scientists at his research institute to come up with a way of getting enough stem cells from a patients blood sample to treat their health issues.

The scientists at SRI went on to develop an FDA compliant method for winding up with as many stem cells in 2 small tubes of blood (drawn from a patient) as are normally obtained from much larger quantities of bone marrow or fat tissue. The blood is exposed to heat, cold, light and electromagnetics which yields 100 million stem cells, an amount which is ten times the minimum of 10 million cells needed to produce a clinical response.

SRIs new method has beenauthorized for use byonly one clinic: Personalized Regenerative Medicine Clinic of San Clemente, California.

Adds Dr. Steenblock, Stem Cell Therapy is experimental and thus is not covered by any insurance plan. This new method is also only available to patients of Personalized Regenerative Medicine Clinic.

Those interested in learning more are invited to call Personalized Regenerative Medicine Clinic (PRMC) at 1-949-367-8870 from 9 am to 4 pm Pacific Time, Monday through Friday. Individuals who enroll as new patients are being offered an initial office visit for free with PRMCs Dr. Donna Hanna.

About David A. Steenblock, D.O., Inc.

Dr. David Steenblock and his Personalized Regenerative Medicine Clinic are both committed to and passionate about advancing medicine. They do this, in part, by creating customized treatment regimens for patients which often includes the use of stem cells and FDA approved stem cell mobilizers and activators. In addition, Dr. Steenblock brings to the table finely honed diagnostic skills as well as a wealth of knowledge, experience, and insight plus the courage to explore, experiment and innovate in a private clinical setting.

The rest is here:
Steenblock Research Institute Announces New Method of Obtaining ... - PRUnderground (press release)

20 Years After Dolly the Sheep, Potential of Cloning Remains Unclear – FOX40

By Embryonic Stem Cells

(CNN) On February 22, 1997, the world learned about a secret project that scientists at the Roslin Institute in Scotland had been working on.

More than seven months earlier, on July 5, 1996, they had aided a Scottish Blackface sheep in giving birth to a Finn Dorset lamb codenamed 6LL3.

She was the first mammal to ever be cloned from the cells of an adult animal.

Using a breakthrough technique called somatic cell nuclear transfer, scientists at Roslin took a nucleus the part of the cell that contains most of its genetic information from cells within the mammary gland of an adult sheep and stuck it inside an unfertilized egg from which the nucleus had been removed.

EDINBURGH, SCOTLAND JULY 05: Sophie Goggins from the National Museums Scotland views Dolly the Sheep during the opening of a major new development at the National Museum of Scotland on July 5, 2016 in Edinburgh,Scotland. The National Museum of Scotland today opened ten new galleries devoted to science, art and design, as part of 14.1m project which increased its exhibition space by almost half and putting many treasures from its collections on display for the first time. (Photo by Jeff J Mitchell/Getty Images)

They stimulated the egg to develop into an embryo and planted the embryo into a surrogate mother. The lamb was dubbed Dolly, a nod to country music legend Dolly Parton and her famously ample bosom.

Years later, that same cell cluster was used to make four other sheep just like Dolly.

Revealing Dolly

The lab had kept her birth secret for seven months to make the announcement coincide with the publication of the scientific paper describing the experiments that produced her, they said.

That week, they recall, they received 3,000 phone calls from all over the world, according to the Roslin Institute.

Much of the news reports had focused not on cloning sheep but on its potential for humans, said Alan Colman, who is now a visiting scholar in the Harvard University Department of Stem Cell and Regenerative Biology.

At the time, Colman was research director at PPL Therapeutics, which specialized in producing transgenic (genetically engineered) livestock.

Wed underestimated the impact the announcement would make, he said. It was something we had prepared for, but we had been totally overwhelmed by the response.

Dollys legacy

Previously, cloning had been done using only embryonic cells, and now researchers had showed that it was possible in cells from another part of the body and adult body.

At the time she was born, I was ecstatic, because no one had previously been able to use nuclear transfer to make an adult vertebrate from an adult cell, Colman said.

Despite the headlines, cloning a mammal wasnt the teams main goal. They were out to develop a more efficient way to produce genetically modified livestock.

In fact, Dolly wasnt even the first to ever be cloned. She was the first mammal cloned from an adult cell.

But scientists have learned a lot since developing the technique, and somatic cell nuclear transfer has been used in more than 20 species to make clones.

The Roslin Institute explained that people have long been motivated to try cloning to make copies of the very best animals for agricultural purposes. Also, since the mid-1980s, there has been an interest in making new uses for farm animals, including producing human proteins in the milk of transgenic cows or sheep for medicinal use in humans.

South Koreas Sooam Biotech Research Foundation have even cloned dogs.

But by and large, scientists dont see a need to clone humans.

Instead, they are using what they learned from creating Dolly to make advancements in stem cell therapy, such as to create embryonic stem cells directly from a patients own cells. They can then study the progression of whichever disease the patient has.

Concerns

Dolly herself lived out her days at the Roslin Institute and was able to produce six lambs.

But she was euthanized at age 6 after being diagnosed with progressive lung disease and after a long battle with arthritis.

Finn Dorset sheep usually live 10 to 11 years, and her health problems seemed to confirm fears that cloned animals would age faster and die prematurely compared with animals born naturally.

This was further exemplified by Dollys four cloned sisters, who were recently euthanized because they too began to show symptoms of osteoarthritis.

OA, as you may know, is a progressive disease, and we took appropriate measures to manage the condition at the time under veterinary guidance, said Kevin Sinclair, a developmental biologist at the University of Nottingham who led research on the sheep.

These animals were in their 10th year and so coming towards the end of their natural lifespan.

A recent study of the remaining clones, however, found that they aged the same as naturally born sheep.

To investigate this further, the team at Nottingham will now conduct postmortem examinations to truly understand whats going on inside the animals.

The final phase of our study involves detailed postmortem analyses of different tissues and organs in order to gain a better insight into the aging process in these animals, Sinclair said.

The Roslin Institute donated Dollys body to the National Museum of Scotland, where she stands to this day.

View post:
20 Years After Dolly the Sheep, Potential of Cloning Remains Unclear - FOX40

Harvard scientist worries we’re ‘reverting to a pre-Enlightenment form of thinking’ – Washington Post

By Embryonic Stem Cells

George Q. Daley, the newhead of Harvard Medical School,knows what it's like when presidential politics collides with science.Daleywasa leading stem cell scientistback in 2001 when President George W. Bush suddenly barred federal funding for research on new embryonic stem cells a gesture to Republican antiabortion backers that, many believe, put a chill onone of the most cutting-edge areas of biology.

The move turned many scientists, unexpectedly, into activists. The diplomatic Daley helpedHarvard create an institute in 2004 towork around the federal funding restrictions;Californiabucked the Bush administration bydevotingits ownstate funds to the research. President Barack Obamaeventuallyreversed the executive orderin 2009,allowing federal funds to be used;today, embryonic stem cell based therapies are being tested in clinical trials, and studying them has helped unleash a wave of newmedicalinsights.

As of Jan. 1,Daley occupies one of the highest-profile jobs in American medicine, a de facto spokesman both for research and medical practice. And he arrives at a moment when the entire field is nervous about what the Trump administration has in store. The White House seems not only indifferent to research, but also actively hostile to some strains of science; the future of theAffordable Care Actis uncertain at best.Drug prices,immigration and the national researchbudget all issues crucial to the medical field are all up for debate.By nature ascientist, accustomed togathering evidence before opining about solutions,Daley says he thinks his experiences working in a field that was marginalized by politicians may provide some useful lessons for navigating what he called a "cacophony of confusion and alternative facts."

Daley spoke to The Washington Post about his hopes and concerns as he takes the helm at Harvard Medical School around the same time as President Trump. This interview has been edited for clarity and length.

Right now, theres uneasiness in the scientific and medical communities over how evidence and research will be treated, ranging fromvaccines to climate change. Having lived through a time when your work was directly politicized and targeted, what are yourthoughts about how to approach a situation like that?

I think that the lessons that I learned in the early challenges and policy debates around embryonic stem cells have a lot to teach us for how to advocate forcefully in todays world. We have to, as scientists, stick to our message, which is that science and evidence is the way to make informed decisions whether those decisions are about advancing human health and wellness, or about advancing the environment and maintainingnot only healthy air quality, but reducing risks to catastrophic climate change. These are all fundamentally, at some level, challenges and risks to human health.

If I had one worry, as we see the cacophony of confusion and alternative facts, it's that were reverting to a pre-Enlightenmentform of thinking, which will take us back to the days of blood-letting and faith-healing. And this is wrong. This is not the way to advance health and wellness for the greatest number, not a way to face our challenges. We are facing some of the greatest global challenges today not just with global warming, but with threats to emerging pathogens, whether its Ebola or Zika. And if we start to question the nature and value of things like vaccines in human health, how are we going to be able to confront the challengesof new pathogens?

[Why Americas health-care spending is projected to soar over the next decade]

Do you think thatthis is something that's already happening, or is it a future worry?

The storm clouds are on the horizon. If I just speak to one issue that has a very direct effect on our community: Our biomedical research enterprise, as well as our clinicians draw on the best and brightest, from not only the United States, but around the globe. We are a magnet, were seen as the beacon of the best, cutting-edge research and the most effective and impactful clinical training and health care delivery. Ive met with students from Iran and Syria who are here studying and about to graduate. And theyre worried that their parents are not going to be able to come see them receive their PhD or their MD. Were worried about the pipeline not only of trainees who keep us at the cutting edge, but patients. Our health care centers are magnets for patients from all over the world, and in many cases from theMiddle East, and it stands in the way of our mission.

The immigration policy of the Trump administration is evolving as we speak, but it soundslike you're worried aboutthe message that recent actions send.

Our concern is that there is a megaphone that screams across the globe. Over the couple-hundred-year history of our country, it has been emblazoned on the Statue of Liberty: Give us your tired, your poor. We are a welcome beacon to immigrants from all across the globe; thats been the message that has built our country. And now the recent message that has been sent is giving pause to those folks in other parts of the world, making them think twice about whether this is a welcoming community for them. Ive already heard that some of our applicants to post-doctoral positions or training programs in our graduate schools are starting to be diverted to programs in Europe that aresaying, "Hey, what can we do to take advantage of the talent pool that might not be going to the United States." That is chilling to me.

What are your thoughts on the plans to repeal the Affordable Care Act and what should come next?

We now have, in Massachusetts, 96 percent of people covered, and I do think thats created a sense in our medical students and our residents and our trainees, and even up to our faculty, that universal access [to health care] is a human right. I remember in my times in the hospital, there was something absolutely wonderful about the fact the homeless person coming off the street with a heart attack got the same intense, compassionate care as the Berkeley professor who had a heart event at Logan Airport and thats an actual case that took place when I was in training. Theres probably no other experience in my time as at trainee at theHarvard hospitals that made me feel more proud about the mission of Harvard medicine. I think thats an aspiration there was an attempt by the Obama administration to capture thatas an aspiration, as the noblest calling of medicine, and I think that anything that is put in it place has to attempt to meet those same aspirations.

Stem cell science has come under political attack in the past, and Vice President Pence has said he opposesembryonic stem cell research. Are you worried about the future of your field?

I always felt very strongly and passionately, as an advocate for stem cell research of all kinds. To be able to use the new technology and biology of regenerative medicine to serve the relief of suffering and the treatment of disease, I just think is a very noble calling. Ive always argued that we need to exploit every possible advantage in the fight against disease.I would continue to advocate for research on all sorts of stem cells. And if there is an attempt to restrict the research in the future, I will be out there again, speaking from the scientific and medical perspective to justify this work.

View original post here:
Harvard scientist worries we're 'reverting to a pre-Enlightenment form of thinking' - Washington Post

Annual Summit on Cell Therapy and Molecular Medicine …

By Uncategorized

Sessions/Tracks

Track 1: Cell Therapy

Cell therapy or cytotherapy is the transfer of cells into a patient with a goal of improving the disease. From beginning blood transfusions were considered to be the first type of cell therapy to be practised as routine. Later, Bone marrow transplantation has also become a well established concept which involves treatment of many kind of blood disorders including anemia, leukemia, lymphyoma and rare immunodeficiency diseases. Alternative medical practitioners perform cell therapy in the form of several different names including xenotransplant therapy, glandular therapy, and fresh cell therapy. It has been claimed by the proponents of cell therapy that it has been used successfully to repair spinal cord injuries, strengthen weaken immune system, treats autoimmune diseases like AIDS, help patients with neurological disorders like Alzheimers disease, parkinsons disease and epilepsy.

Related Conferences

3rd International Conference & Exhibition on Tissue Preservation and Biobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8th World Congress and Expo on Cell & Stem Cell Research, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit on Cell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd World Biotechnology Congress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society of Gene & Cell therapy (NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society for Gene and Cell Therapy (BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19th International Conference on Cell and Gene Therapy ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7th Spring Meeting Viral vectors and vaccines, March 16-17, 2017, Washington, DC and 2nd Annual Genome Editing & Engineering Conference, Feb 6-7 2017, San Diego, CA.

Track 2: Gene Therapy

Gene therapy basically involves the introduction or alteration of genetic material within a cell or organism with an intention of curing the disease. Both cell therapy and gene therapy are overlapping fields of biomedical research with the goals of repairing the direct cause of genetic diseases in DNA or cellular population respectively. The discovery of recombinant DNA technology in the 1970s provided tools to efficiently develop gene therapy. Scientists use these techniques to readily manipulate viral genomes, isolate genes and identify mutations involved in human disease, characterize and regulate gene expressions, and engineer various viral and non viral vectors. Various long term treatments for anemia, haemophilia, cystic fibrosis, muscular dystrophy, Gauschers disease, lysosomal storage diseases, cardiovascular diseases, diabetes and diseases of bones and joints are resolved through successful gene therapy and are elusive today.

Related Conferences

Annual Summit onCell Signaling and Cancer Therapy, Sep 27-28, 2017, Chicago, USA; AnnualSummit on Cell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA;2nd World Biotechnology Congress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition on Tissue Preservation and Biobanking, Aug 23-24 2017, San Francisco, USA; 8thWorld Congress and Expo on Cell & Stem Cell Research, March 20-22, 2017, Orlando, Florida, USA; 10th Australasian Gene Therapy Society Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society of Gene and Cell Therapy (ESGCT), Berlin, Germany.

Track 3:Molecular Medicine

Molecular Medicineis a branch of medicine that develops ways to diagnose and treat diseases by understanding the ways genes, proteins and other cellular molecules work. It is a broad field where physical, chemical, biological,bioinformatics, and medical techniques are used to describe molecular structures and mechanisms, identify fundamental molecular and genetic errors of the disease, and to develop molecular interventions to correct them. Molecular Medicine has now a days proved to be an exciting field of research as some of the recent advancements has led to improved clinical benefits for human health. These are LPS- induced inflammatory response is suppressed by Wnt inhibitors, Dickkopf-1 and LGK974, Selective inhibition ofEbolaentry with selective estrogen receptor modulators by disrupting the endolysosomal calcium, ApoA-IV improves insulin sensitivity and glucose uptake in mouse adipocytes via PI3K-Akt Signalling and many more.

Related Conferences

AnnualSummit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil;3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago , USA;8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA;Annual conference of British Society forGeneandCell Therapy(BSGCT), May 3-6, 2017, Cardiff, Wales, UK; International Society forCellular Therapy(ISCT) 23rdAnnual Meeting, May 10-13, 2017, London, UK; American Society ofGeneandCell Therapy(ASGCT) 20thAnnual Meeting , May 14-19, 2017, Washington, DC; Gordon Research Conference:Viruses&Cells, May 17-19, 2017, Lucca, Italy and WorldAdvanced TherapiesandRegenerative MedicineCongress 2017, May 24-26, 2017, London, UK.

Track 4:Immunotherapy

Due to rapidly advancing field of cancer immunology in past few years, there has been production of several new methods of treating cancer called Immunotherapies. Immunotherapy is a type of treatment that increases the strength of immune response against tumors either by stimulating the activities of specific components of immune system or by counteracting signals produced by cancer cells that suppress immune responses. Some types of immunotherapy are also called as biologic therapy or biotherapy. Recent advancements in cancer immunotherapies have provided new therapeutic approaches. These include tumor-associated macrophages as treatment targets in oncology, in-situ activation of platelets with checkpoint inhibitors for post-surgical cancer immunotherapy, immune checkpoint blockade and associated endocrinopathies and many more.

Related Conferences

3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society ofGene&Cell therapy(NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society forGeneandCell Therapy(BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19thInternational Conference onCellandGene Therapy ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7thSpring Meeting Viral vectorsandvaccines, March 16-17, 2017, Washington, DC and 2ndAnnualGenome Editing&EngineeringConference, Feb 6-7 2017, San Diego, CA.

Genetic Medicine orMedical Geneticsis the branch of medicine that differs from human genetics, and involves the diagnosis and management of hereditary disorders. Human genetics may or may not apply to medicine, but medical genetics refers to the application of genetics to medical care. Genetic Medicine basically involves different areas such asgene therapy, personalized medicine, predictive medicine and the rapidly emerging new medical specialty. Now a days, medical genetics has wide range of scopes in many conditions involving birth defects and dysmorphology,autism, mental retardation, skeletal dysplasia, mitochondrial disorders, cancer genetics, connective tissue disorders and some more.

Related Conferences

Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; AnnualSummit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA;2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA; 10thAustralasianGene TherapySociety Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society ofGeneandCell Therapy(ESGCT), Berlin, Germany.

Track 6: Clinical Trials in Cell and Gene Therapy

A clinical trial is a research study that tests how well new medical approaches work on people and determines if a treatment is safe and effective. The new cell and gene therapies (CGTs) that are advancing from the laboratory into early phase clinical trials has proven to be a complex task even for experienced investigators . As a result of wide variety of CGT products and their potential applications, a case by case assessment is warranted for the design of each clinical trial. Some of the latest and advanced clinical trials include safety and efficacy trial of AAV gene therapy in patients with CNGA3 Achromatopsia, A clinical trial for treatment of Aromatic L- Amino acid Decarboxylase (AADC) deficiency using AAV2-hAADC- An expansion and Glypican 3-specific Chimeric antigenic receptor expressed in T cells for patients with pediatric solid tumors.

Related Conferences

AnnualSummit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil;3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago , USA;8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA;Annual conference of British Society forGeneandCell Therapy(BSGCT), May 3-6, 2017, Cardiff, Wales, UK; International Society forCellular Therapy(ISCT) 23rdAnnual Meeting, May 10-13, 2017, London, UK; American Society ofGeneandCell Therapy(ASGCT) 20thAnnual Meeting , May 14-19, 2017, Washington, DC; Gordon Research Conference:Viruses&Cells, May 17-19, 2017, Lucca, Italy and WorldAdvanced TherapiesandRegenerative MedicineCongress 2017, May 24-26, 2017, London, UK.

Track 7: Cell Therapy Bioprocessing

Cell Therapy Bioprocessing activity mainly focuses to accelerate the safe, cost- effective translations and clinical efficacious of cell therapies into commercial products. This activity covers the entire range of cell therapy activities as well as tissue engineering. In order to succeed, commercial success of at least a few late-stage products are required to develop which will be funded to develop next generation tools and technologies for this field. Recent achievements include, preclinical filing for Phase 1 clinical trials for cell therapy in acute spinal cord injury, clinical proof of concept studies in tissue- engineered trachea, clinical trials for tissue-engineered larynx and routine clinical practice in the regeneration of corneas. The future research priorities will focus on novel cell and bioprocess engineering techniques in order to improve the manufacturing efficacy and methods for health technology assessment to support rapid clinical adoption of new cell therapies.

Related Conferences

3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit onCell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society ofGene&Cell therapy(NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society forGeneandCell Therapy(BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19thInternational Conference onCellandGene Therapy ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7thSpring Meeting Viral vectorsandvaccines, March 16-17, 2017, Washington, DC and 2ndAnnualGenome Editing&EngineeringConference, Feb 6-7 2017, San Diego, CA.

Cell and Gene Therapy products manufacturing focuses on various strategies like the manufacturing process must protect the product, patient, should focus on product characterization, process control, high throughput and parallel processing to achieve scale. The process/analytical development throughout clinical trials involve ongoing, iterative development of manufacturing process and characterization of profile and FDA expecting increasing control and characterization as clinical development progresses. Steps involved in individualized manufacturing and running in parallel for high throughput involves cell selection, expansion, activation, centrifugation and cryopreservation.

Related Conferences

Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; AnnualSummit onCell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA;2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA; 10thAustralasianGene TherapySociety Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society ofGeneandCell Therapy(ESGCT), Berlin, Germany.

Track 9: Rare Diseases & Orphan drugs

Rare diseases are life-threatening or chronically debilitating conditions, affecting no more than 5 in 10,000 persons in the European Community according to the Regulation (EC) N. 141/2000 of the European Parliament and of the Council. It is estimated that between 6000 to 8000 distinct rare diseases affect up to 6% of the total EU population. Therefore, these conditions can be considered rare if taken individually but they affect a significant proportion of the European population when considered as a single group. Several initiatives have been taken at international, European and national level to tackle public health as well as research issues related to diagnosis, prevention, treatment and surveillance of these diseases. An Orphan drug can be defined as the one that is used to treat an orphan disease. An orphan disease in USA is defined as the one that affects fewer than 200000 individuals, but in Japan the number is 50,000 and in Australia is 2000. In past 20 years efforts have been made to encourage companies to develop orphan drugs. The Orphan Drug Act in the USA (1983) was succeeded by similar legislation in Japan (1985), Australia (1997), and the European Community (2000). The encouragement takes three forms: tax credits and research aids, simplification of marketing authorization procedures, and extended market exclusively.

Related Conferences

Annual Summit onCell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil;3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA;8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA;Annual conference of British Society forGeneandCell Therapy(BSGCT), May 3-6, 2017, Cardiff, Wales, UK; International Society forCellular Therapy(ISCT) 23rdAnnual Meeting, May 10-13, 2017, London, UK; American Society ofGeneandCell Therapy(ASGCT) 20thAnnual Meeting , May 14-19, 2017, Washington, DC; Gordon Research Conference:Viruses&Cells, May 17-19, 2017, Lucca, Italy and WorldAdvanced TherapiesandRegenerative MedicineCongress 2017, May 24-26, 2017, London, UK.

Stem cells can self renew themselves and differentiate or develop into more specialised cells. They are the foundation for every organ and tissue in our body. Due to this ability of the stem cells, they have tremendous promise to help us understand and treat a wide range of diseases, injuries and other health related problems. Bone marrow transplantation is the most widely used stem cell therapy , but some of the therapies are derived from umbilical cord blood are also in use today. Likewise, blood stem cells are used to treat diseases of blood, a therapy that has saved thousands of lives of children with leukemia. Some bone, skin and corneal (eye) injuries and diseases can be treated by grafting or implanting tissues and the healing process relies on stem cells with implanted tissue.Regenerative medicines aims to replace tissues or organs that have been damaged by disease, trauma, or congenital issues which is in contrast to the current clinical strategy that focuses primarily on treating the symptoms. These regenerative medicines have wide appropriateness in treating degenerative scatters including dermatology, cardio vascular, and neuro degenerative diseases. Cell treatment is the quickest developing fragment of regenerative drug and this undeveloped cell treatment is making up the biggest part of this business sector.

Related Conferences

3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit onCell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society ofGene&Cell therapy(NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society forGeneandCell Therapy(BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19thInternational Conference onCellandGene Therapy ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7thSpring Meeting Viral vectorsandvaccines, March 16-17, 2017, Washington, DC and 2ndAnnualGenome Editing&EngineeringConference, Feb 6-7 2017, San Diego, CA.

Cancer is a process where the cells grow aberrantly and this growth of cancer cells results in damage of normal tissues, causing loss of function and often pain. The cancer therapeutic drugs are those drugs that block the growth and spread of cancer by interfering with specific molecules (molecular targets) that are involved in the growth, progression and spread of cancer. Moreover, gene therapy approaches may be designed to directly kill tumor cells using tumor killing viruses, or through the introduction of genes termed as suicide genes into the tumor cells. The Food and Drug Administration (FDA) has approved many cancer therapies in order to treat specific types of cancers. To develop targeted therapies it requires the identification of good targets that is, those targets that play a key role in cancer cell growth and survival. One way to identify potential targets is to compare the amounts of individual proteins in cancer cells with those present in normal cells. Gene silencing has also been designed to inhibit the expression of specific genes which are activated or over expressed in cancer cells and can drive tumor growth, blood vessel formation and allow resistance for chemotherapy.

Related Conferences

Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; Annual SummitSummit onCell Therapyand Molecular Medicine, Sep 27-28, 2017, Chicago, USA;2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA; 10thAustralasianGene TherapySociety Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society ofGeneandCell Therapy(ESGCT), Berlin, Germany.

Track 12:Nuclear Medicine

Nuclear medicineis a branch of medical imaging that involves the application of radioactive substances called radiotracers that are generally injected into the bloodstream, inhaled or swallowed. Theradiotracerthen travels through the area being examined and gives off energy in the form of gamma rays, which are detected by a special camera and a computer to create images of inside the body. It is used to diagnose or determine the severity of or treat different types of diseases like many types of cancers, heart disease, neurological disease, gastrointestinal disease, and other abnormalities inside the body. As nuclear medicine techniques are able to identify molecular activity within the body, they offer the capability to detect diseases in its very early stages as well as a patients immediate response to therapeutic interventions. There are two most common imaging methods in nuclear medicine, one isSingle Photon Emission Computed Tomographyor SPECT and the other is Positron Emission Tomography or PET scans.

Related Conferences

AnnualSummit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil;3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago , USA;8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA;Annual conference of British Society forGeneandCell Therapy(BSGCT), May 3-6, 2017, Cardiff, Wales, UK; International Society forCellular Therapy(ISCT) 23rdAnnual Meeting, May 10-13, 2017, London, UK; American Society ofGeneandCell Therapy(ASGCT) 20thAnnual Meeting , May 14-19, 2017, Washington, DC; Gordon Research Conference:Viruses&Cells, May 17-19, 2017, Lucca, Italy and WorldAdvanced TherapiesandRegenerative MedicineCongress 2017, May 24-26, 2017, London, UK.

Track 13: Advances in Cell Engineering, Imaging and Screening

In recent times, advancements in cell engineering, imaging and screening has reached a great height in the field of science & technology and also in the business world. It has attracted many scientists from academia and also established or emerging companies in the field to present their latest scientific achievements and exciting technological solutions through presentations in several sessions. This has helped in improving the scientific knowledge among the people, scientists, researchers and exhibitors from all over the world thus enhancing their scientific curiosity and providing robust solutions against technological issues.

Related Conferences

3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017 in Orlando, Florida, USA; Annual Summit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA; 2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; Spring Symposium of the Netherlands Society ofGene&Cell therapy(NVGCT), 17 March 2017, Lunteren, The Netherlands; British Society forGeneandCell Therapy(BSGCT) Public Engagement 2017, March 27-28, 2017 Oxford, UK; 19thInternational Conference onCellandGene Therapy ICCGT 2017, April 19-21, 2017, Singapore; International Society for BioProcess Technology 7thSpring Meeting Viral vectorsandvaccines, March 16-17, 2017, Washington, DC and 2ndAnnualGenome Editing&EngineeringConference, Feb 6-7 2017, San Diego, CA.

Track 14: Synthetic Biology and Genetic modifications of cells

Synthetic Biology is one of the emerging field of research that can be broadly described as the design and construction of novel artificial biological pathways, organisms or devices or the redesigning of existing natural biological systems. Genome editing with engineered nucleases is a type of genetic engineering in which DNA is either inserted, replaced or deleted in the genome of an organism using engineered nucleases or molecular scissors. These nucleases hence create site specific double stranded breaks (DSBs) at desired locations in the genome. The induced double stranded breaks are repaired through non homologous end- joining (NHEJ) or homologous recombination (HR), thus resulting in targeted mutations (edits). Scientists now a days use various engineered nucleases in order to bring desired changes in the human genome.

Related Conferences

Annual Summit onCell Signalingand Cancer Therapy, Sep 27-28, 2017, Chicago, USA; Annual SummitSummit onCell TherapyandMolecular Medicine, Sep 27-28, 2017, Chicago, USA;2nd WorldBiotechnologyCongress, Dec 4-5 2017, Sao Paulo, Brazil; 3rd International Conference & Exhibition onTissue PreservationandBiobanking, Aug 23-24 2017, San Francisco, USA; 8thWorld Congress and Expo onCell&Stem CellResearch, March 20-22, 2017, Orlando, Florida, USA; 10thAustralasianGene TherapySociety Meeting (AGCTS), October 17-20, 2017, Sydney, Australia; XXV Congress of the European Society ofGeneandCell Therapy(ESGCT), Berlin, Germany.

Biobanking 2016

Sensing the raising importance of Biobanks,Conference LLChosted the 2nd International Conference & Exhibition on Tissue Preservation and Biobanking(Biobanking-2016), duringSeptember 12-13, 2016inPhiladelphia, USAwith a theme Global Innovations in Tissue preservation and Biobanking Technologies. Benevolent response and active participations were received from the Editorial Board Members of Conference LLC Journals as well as from the Biobank project managers, Embryologists, Hematologists, Stem Cell researchers, Scientists, Doctors, Students and Leaders from the fields of Cell and Stem Cell Research, who made this event inspiringly successful.

TheBiobanking-2016 Conferencewas carried out through various sessions with discussions on the following thought provoking and cerebrating scientific tracks:

Human cancer biobank

Biorepository & Biospecimen

Disease based biobank

Cryopreservation Methods

Vitrification

Brain Banking

Biobank Ethics

Biobank in Microbiology

Next Generation Biobanking

Biobank in Genomics

Fertility biobanks

Germplasm Bank

Immune banking

Biobank Applications

Biobanking Informatics

Market Analysis in Biobanking

Tissue engineering

. Stem cell Biobanking

The Organizing Committee would like to thank the moderatorDr.Mary A Hall,UT health sciences, USAandDr. Elena Salvaterra,Air liquide Sanit Service, Italyfor their contribution which resulted in smooth functioning of the conference.

The conference was initiated and embarked with an opening ceremony followed by Keynote presentations, workshop and a series of lectures delivered by both Honorable Guests and members of the Keynote forum. The peerless people who promulgated the theme with their Keynote presentations were;

Kelvin GM Brockbank-Ice-free banking by vitrification of tissues(Tissue Testing Technologies LLC, USA)

Simone Chevalier- The Quebec procure prostate cancer biobank: A unique resource for comprehensive studies of the disease(McGill Urology Director of Research, Canada)

Stephen C Peiper-Biospecimen repository genomic annotations in the precision medicine era(Thomas Jefferson University, USA)

Fiorella Guadagni-Biobanks as a pivotal research infrastructure in precision medicine (San Raffaele Rome University, Italy)

Yoed Rabin-Mechanical stress and structural integrity in vitrification(Carnegie Mellon University, USA)

Mitchel C. Schiewe-Applying the KISS principle with vitrification: Safety and quality control concerns in assisted reproductive technologies(Ovagen Fertility, USA)

Various sessions were chaired and co-chaired by: Kelvin GM Brockbank (Tissue Testing Technologies LLC, USA);Simone Chevalier (McGill Urology Director of Research, Canada), USA; Charles W Wang, (Shanghai Jiao Tong University, China);Yaffa Rubinstein (National Institute of Health, USA).

Conference Series LLC has taken the privilege of felicitating Biobanking-2016 Organizing Committee, Editorial Board Members and Keynote Speakers who supported for the success of this conference.

The esteemed guests, keynote speakers and researchers shared their innovative research and vast experience through their informative presentations at the podium ofBiobanking-2016.We are glad to inform that all accepted abstracts for the conference have been published inJournal of Tissue Science & Engineering: Open Accessas a special issue.

We are also obliged to various experts, company representatives and other eminent scientists who supported the conference by facilitating the discussion forums. We sincerely thank the Organizing Committee Members for their gracious presence, support, and assistance. With the unique feedback from the conference,Conference Series LLC would like to proudly announce the commencement of the 3rd International Conference & Exhibition on Tissue Preservation and Biobanking" to be organized duringAugust 23-24, 2017atSan Francisco, USA.

Mark your calendars for the upcoming Conference; we are hoping to see you soon!

For more details:http://biobanking.conferenceseries.com/

Follow this link:
Annual Summit on Cell Therapy and Molecular Medicine ...

TxCell raises cash for first-in-man CAR-Treg cell therapy study – BioPharma-Reporter.com

By Uncategorized

TxCell has raised 11m ($11.6m) through a share issue which it will use to fund first-in-man study of one of its cell therapy candidates.

The shares were bought by new backers like Auriga Ventures II and ING Luxembourg a S.A. as well as existing TxCell investors Innobio FCPR andBpifrance Participation Large Venture.

CEO Stephane Boissel told us "TxCell hasrealigned its strategy, being the first to move into the Car-Treg field in auto-immune diseases. Thefinance will help TxCell to get through to a first IND approval to initiate a first-in-man study with a CAR-Treg candidate, which is expected by the end of 2018.

He added that: "This study will be a world first. It most likely would be in solid organ transplantation, to treat or prevent chronic rejection.

TxCell has four CAR-Treg candidates in his pipeline. Three are for the treatment of diseases, specifically lupus nephritis, bullous pemphigoid and multiple sclerosis. The fourth is designed to prevent graft-versus-host disease after transplantation.

All four were developed using the firms ENTrIA platform which uses CARs to direct antigen-specific regulatory cells (Ag-Tregs) to target autoimmune inflammatory diseases.

All four are listed as being in early phase development on TxCells website.

Two of the therapies, the GvHD treatment ENTX#SOT and the lupus candidate ENTX#LN are the subject of preclinical research accords signed last year.

ENTX#BP, which is being developed as a treatment for the rare skin blistering disease bullous pemphigoid, is also the focus of a preclinical research partnership.

However, when TxCell announced the deal with the Lubeck Institute of Experimental Dermatology (LIED) in June it said the aim was to conduct non-clinical pharmacology studies with CAR-Treg cells to prepare for a first-in-man study.

Original post:
TxCell raises cash for first-in-man CAR-Treg cell therapy study - BioPharma-Reporter.com

Heart failure BREAKTHROUGH: Stem cells trial offers hope to millions – Express.co.uk

By Stem Cell Treatment

GETTY

A high-level meeting has paved the way for global trials to begin on hundreds of patients.

British scientists have found a way to use stem cells to repair damaged tissue which could help millions living with heart failure, the UKs leading cause of death.

Scarring due to disease or heart attacks affects more than two million people in Britain.

This would be the biggest breakthrough since the first transplants three decades ago

Professor Steve Westaby

Initial trials involving more than 100 patients are being planned for the autumn at two London hospitals.

World renowned cardiac surgeon Professor Steve Westaby, who helped pioneer the revolutionary technique, said it had been thought that repairing heart damage was impossible.

But results from a long-term trial that began in Greece five years ago have shown that this is not the case.

Preliminary data from this trial showed the engineered stem cells, known as Heartcel, can reverse scarring by up to 79 per cent.

The data, presented at the European Society of Cell and Gene Therapy in Florence, showed an average of 40 per cent reduction in heart damage in those on the treatment.

Last month researchers finalised talks with European and US regulators to discuss the timetable for global trials next year involving 500 people.

Getty

1 of 7

6 early signs of a heart attack

Professor Westaby, from the John Radcliffe Hospital, Oxford, said: I am very excited at the prospect of a trial which will hopefully lead to the availability of this stem cell treatment to thousands of patients annually in the UK.

Other scientists have tried in vain to repair damaged heart muscle using stem cells over the past few decades.

This is the first time scarring has been shown to be reversible. It could herald an end to transplants and lead to a treatment for heart failure within three to five years.

GETTY

Professor Westaby said: This would be the biggest breakthrough since the first transplants three decades ago.

Professor Westaby has been working on the technique for more than a decade and is carrying out the study with Professor Kim Fox, head of the National Heart and Lung Institute, at Imperial College London.

The implanted stem cells were created by medical outfit Celixir, co-founded by Nobel laureate Professor Martin Evans, the first scientist to culture mice embryonic stem cells in a laboratory.

Professor Westaby was inspired to work on the breakthrough in 1999 after a four-month-old baby girls heart healed itself after he carried out a major life-saving operation.

Kirsty Collier, from Swindon, was dying of a serious and rare heart defect. In a last ditch effort Professor Westaby cut away a third of her badly damaged heart.

GETTY

GETTY

Surprisingly it began to beat. Fourteen years later a scan has shown that the heart had healed itself.

Now Kirsty, 18, has a normal one. Professor Westaby said: She was essentially dead and was only resurrected by what I regarded at the time as a completely bizarre operation.

The fact there was no sign of heart damage told me there were foetal stem cells in babies hearts that could remove scarring of heart muscle. That never happens in adults.

Its all down to the clues we got from Kirstys operation.

Read more:
Heart failure BREAKTHROUGH: Stem cells trial offers hope to millions - Express.co.uk

→←